Market Overview:
The global targeted protein degradation market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The market growth is attributed to the increasing prevalence of chronic diseases, rising demand for personalized medicines, and technological advancements in the field of proteomics. Based on type, the global targeted protein degradation market is segmented into oral, intravenous, and others. The oral segment accounted for the largest share of the global targeted protein degradation market in 2017 and is projected to grow at a CAGR of 11% during the forecast period. This growth can be attributed to factors such as growing preference for orally administered drugs owing to their ease-of-use and lower side effects as compared with injectable drugs; rising incidence of chronic diseases; and increasing R&D expenditure by pharmaceutical companies on novel drug discovery programs. Based on application, the global targeted protein degradation market is segmented into hospital and research institute segments.
Product Definition:
Targeted protein degradation is the process by which proteins are specifically recognized and degraded by the proteasome. The proteasome is a large complex of proteins that degrade other proteins in the cell. The importance of targeted protein degradation is that it allows for the selective destruction of specific proteins, which can be important for regulating cellular function.
Oral:
Oral is a new term in the field of biotechnology and medicine. It basically means that the drug or protein can be taken by mouth (in case of humans). In contrast to injectable, oral administration allows for sustained action over a longer period of time. The advantages include ease in terms of dosage form, increased bioavailability due to higher absorption rate and it also helps reduce side effects caused due to rapid metabolism by liver cells.
Intravenous:
Intravenous is a fluid route of drug administration which involves IV infusion. It allows the drugs to be administered directly into the bloodstream allowing it to reach all organs quickly. Intravenous can also be used for continuous or repeated dosing without any interruption in care giving. The most common use of intravenous is in parenteral nutrition and as a delivery system for medications, vaccines, and fluids such as rehydration solutions among others (1).
Application Insights:
The hospital application segment held the largest share of more than 60.0% in 2017. Targeted protein degradation is used as a therapeutic tool for the treatment of patients with acute kidney failure, sepsis, and other life-threatening conditions. The intravenous targeted protein degradation technique is majorly used for treating these life-threatening conditions due to its high success rate and efficiency in eliminating infectious organisms from the body (1).
Hospital applications are expected to witness significant growth over the forecast period owing to rising incidences of chronic diseases such as cancer and diabetes that require regular medical monitoring & treatments along with a wide range of prescription drugs that need frequent dosage alterations throughout the day (2). This has led to an increase in demand for targeted proteomics tests across hospitals worldwide.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of biopharmaceutical companies, which are engaged in protein degradation research for drug development. Moreover, increasing government funding for R&D activities pertaining to protein degradation is also expected to contribute towards regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to factors such as rising disposable income and improving healthcare infrastructure in emerging countries such as China and India. In addition, an increase in investments by leading players for product development will further drive this regional market during the forecast period.
Growth Factors:
- Increasing demand for targeted protein degradation products owing to their ability to degrade specific proteins with high precision and efficiency
- Growing research and development activities in the field of targeted protein degradation that is expected to lead to the development of novel products and applications
- Rising number of partnerships and collaborations between companies involved in targeted protein degradation market for the development and commercialization of new products
- increasing investments by leading players towards expanding their product portfolios as well as strengthening their presence in key markets
- Growing awareness about benefits offered by targeted protein degradation products among researchers, pharmaceutical companies, biotechnology firms, etc., which is likely to boost demand for these products over the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Targeted Protein Degradation Market Research Report
By Type
Oral, Intravenous, Others
By Application
Hospital, Research Institute
By Companies
5AM Venture Management LLC, AbbVie Inc, Almac Group, Amgen Inc., Bayer AG, Biogen Inc., C4 Therapeutics, Cosmo Bio USA, Covance Inc, Eli Lilly and Company, Gilead Sciences, Inc, GlaxoSmithKline plc, Merck KGaA, Mission Therapeutics, Novartis AG, Pfizer Inc, Promega
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
225
Number of Tables & Figures
158
Customization Available
Yes, the report can be customized as per your need.
Global Targeted Protein Degradation Market Report Segments:
The global Targeted Protein Degradation market is segmented on the basis of:
Types
Oral, Intravenous, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Research Institute
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- 5AM Venture Management LLC
- AbbVie Inc
- Almac Group
- Amgen Inc.
- Bayer AG
- Biogen Inc.
- C4 Therapeutics
- Cosmo Bio USA
- Covance Inc
- Eli Lilly and Company
- Gilead Sciences, Inc
- GlaxoSmithKline plc
- Merck KGaA
- Mission Therapeutics
- Novartis AG
- Pfizer Inc
- Promega
Highlights of The Targeted Protein Degradation Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Intravenous
- Others
- By Application:
- Hospital
- Research Institute
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Targeted Protein Degradation Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Targeted protein degradation is a process by which proteins are degraded in order to remove them from the body. This can be done through the action of enzymes, or by the action of microorganisms.
Some of the major players in the targeted protein degradation market are 5AM Venture Management LLC, AbbVie Inc, Almac Group, Amgen Inc., Bayer AG, Biogen Inc., C4 Therapeutics, Cosmo Bio USA, Covance Inc, Eli Lilly and Company, Gilead Sciences, Inc, GlaxoSmithKline plc, Merck KGaA, Mission Therapeutics, Novartis AG, Pfizer Inc, Promega.
The targeted protein degradation market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Targeted Protein Degradation Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Targeted Protein Degradation Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Targeted Protein Degradation Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Targeted Protein Degradation Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Targeted Protein Degradation Market Size & Forecast, 2018-2028
4.5.1 Targeted Protein Degradation Market Size and Y-o-Y Growth
4.5.2 Targeted Protein Degradation Market Absolute $ Opportunity
Chapter 5 Global Targeted Protein Degradation Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Targeted Protein Degradation Market Size Forecast by Type
5.2.1 Oral
5.2.2 Intravenous
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Targeted Protein Degradation Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Targeted Protein Degradation Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Research Institute
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Targeted Protein Degradation Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Targeted Protein Degradation Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Targeted Protein Degradation Analysis and Forecast
9.1 Introduction
9.2 North America Targeted Protein Degradation Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Targeted Protein Degradation Market Size Forecast by Type
9.6.1 Oral
9.6.2 Intravenous
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Targeted Protein Degradation Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Research Institute
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Targeted Protein Degradation Analysis and Forecast
10.1 Introduction
10.2 Europe Targeted Protein Degradation Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Targeted Protein Degradation Market Size Forecast by Type
10.6.1 Oral
10.6.2 Intravenous
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Targeted Protein Degradation Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Research Institute
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Targeted Protein Degradation Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Targeted Protein Degradation Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Targeted Protein Degradation Market Size Forecast by Type
11.6.1 Oral
11.6.2 Intravenous
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Targeted Protein Degradation Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Research Institute
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Targeted Protein Degradation Analysis and Forecast
12.1 Introduction
12.2 Latin America Targeted Protein Degradation Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Targeted Protein Degradation Market Size Forecast by Type
12.6.1 Oral
12.6.2 Intravenous
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Targeted Protein Degradation Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Research Institute
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Targeted Protein Degradation Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Targeted Protein Degradation Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Targeted Protein Degradation Market Size Forecast by Type
13.6.1 Oral
13.6.2 Intravenous
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Targeted Protein Degradation Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Research Institute
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Targeted Protein Degradation Market: Competitive Dashboard
14.2 Global Targeted Protein Degradation Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 5AM Venture Management LLC
14.3.2 AbbVie Inc
14.3.3 Almac Group
14.3.4 Amgen Inc.
14.3.5 Bayer AG
14.3.6 Biogen Inc.
14.3.7 C4 Therapeutics
14.3.8 Cosmo Bio USA
14.3.9 Covance Inc
14.3.10 Eli Lilly and Company
14.3.11 Gilead Sciences, Inc
14.3.12 GlaxoSmithKline plc
14.3.13 Merck KGaA
14.3.14 Mission Therapeutics
14.3.15 Novartis AG
14.3.16 Pfizer Inc
14.3.17 Promega
